Newport Beach, CA (PRWEB) May 08, 2012
Absorption Pharmaceuticals (AP), LLC. is receiving unprecedented media attention for its groundbreaking product PROMESCENT, the over-the-counter , FDA approved, topical treatment for Premature Ejaculation (PE). On April 25th, The Dr. Oz Show with guest expert Dr. Laura Berman featured PROMESCENT as a safe and effective aid in improving sexual intimacy for couples by closing the “arousal gap”. Reaction to the segment was immediate and overwhelmingly positive. The PROMESCENT website was flooded with female visitors who purchased the product for their partners in record numbers. Many women said PROMESCENT has given them hope for a better and more empowered sex life.
On May 3rd, CNN.com featured an article entitled, “PE: The ‘other’ male sexual problem” written by Ian Kerner, Ph.D, a sexuality counselor and New York Times best-selling author of numerous books. Dr. Kerner cited PROMESCENT as a helpful treatment for PE, the #1 men’s sexual health dysfunction. He also cited that PROMESCENT is FDA approved and available unlike PSD502, a topical PE treatment that has been awaiting approval for several years.
Sales of PROMESCENT prior to Dr. OZ and CNN.com were already on track to hit 11 consecutive months of growth. The recent recognition from reputable and established media entities is boosting sales to even more impressive levels.
AP and its premier product, PROMESCENT, had already built a strong foundation of enthusiastic support within the medical community prior to introducing it to the media.
Leading urologists, sexual medicine experts and thought leaders worldwide have been and continue to acknowledge that PROMESCENT is the long awaited, safe and effective treatment for PE sufferers, who number more than 30 million in the US alone.
AP’s CEO Jeff Abraham says, “It has always been a priority as a pharmaceutical company to first win the respect and approval of medical professionals seeking an effective treatment for PE. It is very encouraging to now receive recognition from such high caliber media figures and institutions such as Dr. OZ and CNN.”
For additional media related information please contact:
May Lee/V.P. Media & Marketing
About Absorption Pharmaceuticals (AP), LLC.
Absorption Pharmaceuticals (AP), LLC., founded in 2008 and based in Newport Beach, CA, is the manufacturer of PROMESCENT. The FDA approved treatment under strict monograph guidelines was developed by Dr. Ronald Gilbert, Urologist, Founder and Chief Medical Officer of Absorption Pharmaceuticals. The lidocaine based topical anesthetic utilizes a patented, advanced, transcutaneous absorption technology. Since PROMESCENT’S formal introduction in 2011, it has been enthusiastically embraced by leading experts in the field of sexual medicine and practicing urologists globally. PROMESCENT is currently sold in 42 countries and counting. AP is developing additional international distribution partnerships to continue dramatic sales growth in the coming months. The company’s mission is to be the leader in bringing awareness to the pervasive issue of premature ejaculation and providing the best, most effective treatment available. For general information or product inquires email questions to: info(at)promescent(dot)com
# # #